Propalin (Canada)This page contains information on Propalin for veterinary use.
The information provided typically includes the following:
- Propalin Indications
- Warnings and cautions for Propalin
- Direction and dosage information for Propalin
PropalinThis treatment applies to the following species:
FOR VETERINARY USE ONLY
Active Ingredient (per mL):
Phenylpropanolamine HCl: 50 mg/mL
Bottles of 30 mL and 100 mL.
Propalin is recommended for the long-term treatment of urinary incontinence associated with urethral sphincter incompetence in spayed bitches. The degree of improvement in the symptoms of urinary incontinence may vary between patients. Also, some patients may not respond to therapy.
Phenylpropanolamine is a chemical analogue of the endogenous sympathomimetic amines. It is an α-adrenergic agent which has been reported to increase resting urethral tone in dogs.1 It acts by direct stimulation of the smooth muscle of the internal urethral sphincter.
Dosage - Mode Of Administration
Using the oral syringe included, administer in food or directly in the dog’s mouth, 1 mg/kg bodyweight of phenylpropanolamine HCl (0.1 mL of Propalin Syrup per 5 kg of body weight), 3 times daily.
Not for use in animals on cardiac medication or any other sympathomimetic agent. This drug must also not be used in the presence of concurrent diseases such as hypertension, renal failure or any cardiovascular disorder. Also, it should be used with extreme caution in dogs suffering from glaucoma or diabetes mellitus.
The main adverse effects reported following therapy with phenylpropanolamine are those associated with a stimulation of the sympathetic nervous system. The following syndromes could be seen in descending order of frequency:
- behavioural (aggressive behaviour, restlessness)
- gastrointestinal (vomiting, diarrhea)
- neurological (epileptic episodes, seizures, tremors)
- cardiovascular (asymptomatic tachyarrythmia, cardiovascular collapse).
Also, allergic (hypersensitivity) reactions can occur (swollen eyelids, photophobia) as these were reported in the spontaneous post-marketing reporting to the U.K. Regulatory Agency following the introduction of the product to that market.
Because of these effects, special care should be taken if the animal to be treated has a history of epilepsy, as a stimulation of the sympathetic system may help trigger epileptic crisis in certain cases.
Do not exceed the prescribed dosage. Frequent reevaluations by a veterinarian are recommended while the dog is on phenylpropanolamine therapy. This drug must not be used in breeding, pregnant or lactating dogs.
Suspected drug interactions with phenylpropanolamine include (but are not necessarily limited to) beta-blockers, sympathomimetic and anti-cholinergic agents (including atropine), halothane, insulin, and non steroid anti-inflamatory drugs (NSAIDs). In addition, drugs that affect urine pH may modify urinary excretion of phenylpropanolamine and result in greater or reduced effects of the drug.
Store between 15°C and 25°C.
(1) K.P. RICHTER and G.V. LING: Clinical response and urethral pressure profile changes after phenylpropanolamine in dogs with primary sphincter incompetence. JAVMA, Vol. 187, No. 6, September 15, 1985. 605-611.
*Trademark of Vétoquinol S.A., Vétoquinol N.-A. Inc., Authorized Licensee
Vétoquinol N.-A. Inc., 2000, ch. Georges, Lavaltrie, QC, Canada J5T 3S5
432484 0712 B
NAC No.: 12341584
2000, CHEMIN GEORGES, LAVALTRIE, QC, J5T 3S5
|Every effort has been made to ensure the accuracy of the Propalin information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2014 North American Compendiums. Updated: 2014-12-03